CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-16 | Alenson Carman Principal Accounting Officer | Grant or award · Restricted stock units | +2,800 | 2,800 | ||
| 2018-02-16 | Alenson Carman Principal Accounting Officer | Grant or award · Restricted stock units | +2,370 | 2,370 | ||
| 2018-02-16 | Hoerter Steven L. Chief Commercial Officer | Grant or award · Stock option (right to buy) | +33,000 | 33,000 | ||
| 2018-02-16 | Hoerter Steven L. Chief Commercial Officer | Grant or award · Restricted stock units | +8,250 | 8,250 | ||
| 2018-02-16 | Hirsch Andrew Chief Financial Officer | Grant or award · Stock option (right to buy) | +33,000 | 33,000 | ||
| 2018-02-16 | Hirsch Andrew Chief Financial Officer | Grant or award · Restricted stock units | +8,250 | 8,250 | ||
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Option exercise | +2,000 | $35.16 | $70K | 2,881 |
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Sale | −1,500 | $77.51 | $116K | 1,381 |
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Sale | −500 | $78.08 | $39K | 881 |
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Option exercise · Stock option (right to buy) | −2,000 | 105,000 | ||
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Grant or award · Stock option (right to buy) | +33,000 | 33,000 | ||
| 2018-02-16 | Bowden Christopher Chief Medical Officer | Grant or award · Restricted stock units | +8,250 | 8,250 | ||
| 2018-02-16 | Biller Scott Chief Scientific Officer | Grant or award · Stock option (right to buy) | +33,000 | 33,000 | ||
| 2018-02-16 | Biller Scott Chief Scientific Officer | Grant or award · Restricted stock units | +8,250 | 8,250 | ||
| 2018-02-16 | Schenkein David P Chief Executive Officer | Grant or award · Stock option (right to buy) | +97,500 | 97,500 | ||
| 2018-02-16 | Schenkein David P Chief Executive Officer | Grant or award · Restricted stock units | +24,375 | 24,375 | ||
| 2018-02-05 | Biller Scott Chief Scientific Officer | Option exercise | +64 | $0.47 | $30 | 53,123 |
| 2018-02-05 | Biller Scott Chief Scientific Officer | Option exercise | +2,936 | $9.05 | $27K | 56,059 |
| 2018-02-05 | Biller Scott Chief Scientific Officer | Sale | −799 | $74.89 | $60K | 55,260 |
| 2018-02-05 | Biller Scott Chief Scientific Officer | Sale | −1,100 | $75.70 | $83K | 54,160 |
Page 66 of 80 · 1,590 trades